GlassScriptPhysician profile
Nadeem A Goraya
NPI 1285046854
$1,608.94
in general payments reported to CMS, 2019-2025
20 companies · $457 in 2025
The $457 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $304 · 2020: $48.57 · 2021: $140 · 2022: $273 · 2023: $221 · 2024: $165 · 2025: $457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $843.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $843.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $246.19 | 2019-2025 | Airsupra |
| Novo Nordisk INC | $178.43 | 2021-2022 | |
| Boston Scientific Corporation | $141.60 | 2019 | |
| Abbvie INC. | $123.72 | 2022-2025 | |
| Lilly USA, LLC | $118.44 | 2022-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $109.92 | 2023-2025 | Shingrix, Trelegy Ellipta |
| Biosense Webster, INC. | $103.55 | 2025 | Qdot Micro |
| Exact Sciences Corporation | $82.22 | 2024-2025 | Cologuard Collection Kit |
| Nevro Corp. | $76.74 | 2024 | Senza |
| Hologic Sales and Service, LLC | $74.85 | 2020-2025 | Aptima, Myosure Tissue Removal Device, Acessa Provu System |
| Daiichi Sankyo INC. | $63.04 | 2019-2020 | |
| W. L. Gore & Associates, INC. | $61.67 | 2023 | Gore Excluder Aaa Endoprosthesis |
| Dexcom, INC. | $52.95 | 2024-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $46.27 | 2025 | Freestyle Libre 3 |
| Sun Pharmaceutical Industries INC. | $31.64 | 2023 | Cequa |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $29.72 | 2023-2024 | Altis |
| Dynavax Technologies Corporation | $25.46 | 2023 | Heplisav-B |
| Ge Healthcare | $18.86 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.76 | 2025 | Jardiance |
| Organon LLC | $8.91 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nadeem Goraya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.